Wealth Enhancement Advisory Services’s Aldeyra Therapeutics ALDX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$21.9K	Sell	23,145 -24,373	-51%	-$38.9K	﹤0.01%	4119
2026 Q2	$98.4K	Sell	47,518 -13,569	-22%	-$23.3K	﹤0.01%	3796
2026 Q1	$101K	Buy	61,087 +28,404	+87%	+$124K	﹤0.01%	3319
2025 Q4	$133K	Sell	32,683 -159	-0.5%	-$817	﹤0.01%	3374
2025 Q3	$184K	Buy	32,842 +5,556	+20%	+$29K	﹤0.01%	3168
2025 Q2	$117K	Buy	27,286 +16,376	+150%	+$42.3K	﹤0.01%	3113
2025 Q1	$62.7K	Buy	+10,910	New	+$64.5K	﹤0.01%	2834

Other funds holding ALDX

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.68B AUM 22.33% 1-Year Est. Return

Providence Wealth Advisors Frankfort, Illinois $174M AUM 29.13% 1-Year Est. Return

Hikari Power Tokyo, Japan $439M AUM 11.38% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Wealth Enhancement Advisory Services's ALDX Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its Aldeyra Therapeutics (ALDX) stake by 51% in Q3 2026, selling an estimated $38.9K and leaving 23,145 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4119.

Wealth Enhancement Advisory Services first reported a position in ALDX in Q1 2025 and has held it in 7 quarters since. The position peaked at $184K in Q3 2025. 16 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.

Wealth Enhancement Advisory Services held 23,145 shares of Aldeyra Therapeutics worth $21.9K as of Q3 2026.
Wealth Enhancement Advisory Services sold 24,373 Aldeyra Therapeutics shares in Q3 2026, an estimated $38.9K.
Aldeyra Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #4119 holding.
Wealth Enhancement Advisory Services first reported a position in Aldeyra Therapeutics in Q1 2025 and has held it in 7 quarters since.
Wealth Enhancement Advisory Services's Aldeyra Therapeutics position peaked at $184K in Q3 2025.
16 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.